TABLE 3.
TGF-β superfamily in liver cancer/HCC.
| S.N | Title | Type of article | References |
|---|---|---|---|
| 1 | TGF-β signaling in liver and gastrointestinal cancers | Review | Katz et al. (2013) |
| 2 | TGF-β signaling in liver metastasis | Review | Marvin et al. (2020) |
| 3 | Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis | Review | Fabregat and Caballero-Díaz (2018) |
| 4 | Roles of transforming growth factor-β signaling in liver disease | Review | Wang, X. L. et al. (2024) |
| 5 | TGF-β in progression of liver disease | Review | Dooley and ten Dijke (2012) |
| 6 | Targeting transforming growth factor β signaling in liver cancer | Review | Rao and Mishra (2019) |
| 7 | The TGF-β pathway: A pharmacological target in hepatocellular carcinoma? | Review | Gonzalez-Sanchez et al. (2021) |
| 8 | The rationale for targeting TGF-β in chronic liver diseases | Review | Giannelli et al. (2016b) |
| 9 | TGF-β1 and TGF-β2 abundance in liver diseases of mice and men | Research paper | Dropmann et al. (2016) |
| 10 | TGF-β and HIPPO signaling pathways interplay in distinct hepatic contexts | Review | Color-Aparicio et al. (2024) |
| 11 | The activin axis in liver biology and disease | Review | Rodgarkia-Dara et al. (2006) |
| 12 | Activins and activin antagonists in hepatocellular carcinoma | Review | Deli et al. (2008) |
| 13 | Activins and follistatins: Emerging roles in liver physiology and cancer | Review | Kreidl et al. (2009) |
| 14 | Gastrointestinal pharmacology activins in liver health and disease | Review | Hamang et al. (2023) |
| 15 | Inhibin/activin expression in human and rodent liver: subunits a and bB as new players in human hepatocellular carcinoma? | Research paper | Frost et al. (2011) |
| 16 | Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases | Review | Herrera et al. (2014) |
| 17 | Unveiling the impact of BMP9 in liver diseases: Insights into pathogenesis and therapeutic potential | Review | Chen et al. (2024) |
| 18 | Growth differentiation factor 15: Emerging role in liver diseases | Review | Li et al. (2024) |
| 19 | Expression and function of BMP and activin membrane-bound inhibitor (BAMBI) in chronic liver diseases and hepatocellular carcinoma | Review | Weber et al. (2023) |
| 20 | SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma | Research paper | Hernanda et al. (2015) |
| 21 | The role of TGF-β/SMAD signaling in hepatocellular carcinoma: from mechanism to therapy and prognosis | Review | Xin et al. (2024) |
| 22 | Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma | Research paper | Feng, X. et al. (2015) |
| 23 | Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma | Review | Majumdar et al. (2012) |
| 24 | Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1 | Research paper | Yang et al. (2013) |
| 25 | A transforming growth factor-β and H19 signaling axis in tumor-initiating hepatocytes that regulates hepatic carcinogenesis | Research paper | Zhang et al. (2019) |
| 26 | TGFβR1 inhibition drives hepatocellular carcinoma proliferation through induction of toll-like-receptor signaling | Research paper | Mohamed et al. (2024) |
| 27 | Epithelial transforming growth factor-β signaling does not contribute to liver fibrosis but protects mice from cholangiocarcinoma | Research paper | Mu et al. (2016) |
| 28 | Involvement of programmed cell death 4 in transforming growth factor-β1-induced apoptosis in human hepatocellular carcinoma | Research paper | Zhang et al. (2006) |
| 29 | Ethanol sensitizes hepatocytes for TGF-β-triggered apoptosis | Research paper | Gaitantzi et al. (2018) |
| 30 | Autophagy is activated by TGF-β and potentiates TGF-β-mediated growth inhibition in human hepatocellular carcinoma cells | Research paper | Kiyono et al. (2009) |
| 31 | Transforming growth factor-β induces senescence in hepatocellular carcinoma cells and inhibits tumor growth | Research paper | Senturk et al. (2010) |
| 32 | TGF-β/SMAD canonical pathway induces the expression of transcriptional cofactor TAZ in liver cancer cells | Research paper | Ríos-López et al. (2023) |
| 33 | TGF-β signaling in onset and progression of hepatocellular carcinoma | Review | Meindl-Beinker et al. (2012) |
| 34 | TGF-β and hepatocellular carcinoma: When a friend becomes an enemy | Review | Arrese et al. (2018) |
| 35 | Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-β pathway | Research paper | Chen, J. et al. (2018) |
| 36 | Transforming growth factor-β promotes liver tumorigenesis in mice via upregulation of Snail | Research paper | Moon et al. (2017) |
| 37 | MFSD2A overexpression inhibits hepatocellular carcinoma through TGF-β/Smad Signaling | Research paper | Xiao et al. (2025) |
| 38 | The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects | Research paper | Dropmann et al. (2024) |
| 39 | Differential TGFβ pathway targeting by miR-122 in humans and mice affects liver cancer metastasis | Research paper | Yin et al. (2016) |
| 40 | Transforming growth factor-β drives the transendothelial migration of hepatocellular carcinoma cells | Research paper | Koudelkova et al. (2017) |
| 41 | The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells | Research paper | Moreno-Càceres et al. (2017) |
| 42 | Cholesterol pathway inhibition induces TGF-β signaling to promote basal differentiation in pancreatic cancer | Research paper | Gabitova-Cornell et al. (2020) |
| 43 | Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib | Research paper | Giannelli et al. (2020) |
| 44 | Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing | Research paper | Deshmukh et al. (2021) |
| 45 | TGF-β downstream of Smad3 and MAPK signaling antagonistically regulate the viability and partial epithelial-mesenchymal transition of liver progenitor cells | Research paper | Sun et al. (2024) |
| 46 | Novel transforming growth factor β receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma | Research paper | Faivre et al. (2019) |
| 47 | New and old key players in liver cancer | Review | Cuesta et al. (2023) |
| 48 | Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model | Research paper | Hammad et al. (2018) |
| 49 | Targeting TGF-beta I with the transforming growth factor receptor type I kinase inhibitor, LY2157299, modulates stemness-related biomarkers in hepatocellular carcinoma | Research paper | Rani et al. (2015) |
| 50 | A phase 2 study of galunisertib (TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma | Research paper | Kelley et al. (2019) |
| 51 | Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma | Research paper | Harding et al. (2021) |